Vanina de Verneuil net worth and biography

Vanina de Verneuil Biography and Net Worth

EVP, General Counsel and Corporate Secretary of Vir Biotechnology

Vanina de Verneuil, J.D., serves as Executive Vice President, General Counsel and Corporate Secretary. She joined Vir Biotechnology in 2020 as Vice President, Corporate Law, in 2022, she took on the Senior Vice President, Corporate Law and Interim General Counsel role, and in 2023 was promoted to Senior Vice President, Legal and Corporate Secretary. De Verneuil has two decades of experience representing publicly listed companies and their boards of directors, as well as biopharma investors.

Prior to joining Vir Biotechnology in 2020, De Verneuil was a partner at DLA Piper, a leading international law firm with deep roots in the life sciences industry, where she served as outside counsel to publicly listed companies and biopharma investors. Prior to that, she was Global General Counsel at Reliance Communications (Enterprise)/Global Cloud Xchange, a publicly listed global data communications service provider.

De Verneuil received a B.A. in psychology and French from Duke University, and a J.D. from New York University School of Law.

What is Vanina de Verneuil's net worth?: The estimated net worth of Vanina de Verneuil is at least $486,295.20 as of February 26th, 2025. Ms. de Verneuil owns 79,460 shares of Vir Biotechnology stock worth more than $486,295 as of April 26th. This net worth estimate does not reflect any other assets that Ms. de Verneuil may own. Learn More about Vanina de Verneuil's net worth.
How do I contact Vanina de Verneuil?: The corporate mailing address for Ms. de Verneuil and other Vir Biotechnology executives is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. Vir Biotechnology can also be reached via phone at 415-906-4324 and via email at ir@vir.bio. Learn More on Vanina de Verneuil's contact information.
Has Vanina de Verneuil been buying or selling shares of Vir Biotechnology?: Vanina de Verneuil has not been actively trading shares of Vir Biotechnology over the course of the past ninety days. Most recently, Verneuil Vanina De sold 7,373 shares of the business's stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $9.14, for a transaction totalling $67,389.22. Following the completion of the sale, the executive vice president now directly owns 79,460 shares of the company's stock, valued at $726,264.40. Learn More on Vanina de Verneuil's trading history.
Who are Vir Biotechnology's active insiders?: Vir Biotechnology's insider roster includes Marianne De Backer (CEO & Director), Vanina de Verneuil (EVP, General Counsel and Corporate Secretary), Ann Hanly (CTO), Howard Horn (CFO), Robert More (Director), Janet Napolitano (Director), Phillip Pang (Insider), Jay Parrish (Insider), Saira Ramasastry (Director), Steven Rice (Insider), Vicki Sato (Director), George Scangos (CEO), and Herbert Virgin (EVP). Learn More on Vir Biotechnology's active insiders.
Are insiders buying or selling shares of Vir Biotechnology?: In the last twelve months, insiders at the sold shares 10 times. They sold a total of 130,587 shares worth more than $972,578.37. The most recent insider tranaction occured on April, 3rd when CEO Backer Marianne De sold 79,712 shares worth more than $474,286.40. Insiders at Vir Biotechnology own 15.6% of the company. Learn More about insider trades at Vir Biotechnology.
Information on this page was last updated on 4/3/2025.

Vanina de Verneuil Insider Trading History at Vir Biotechnology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/26/2025	Sell	7,373	$9.14	$67,389.22	79,460
12/2/2024	Sell	76	$8.22	$624.72	56,973
11/5/2024	Sell	2,347	$9.47	$22,226.09	61,370
11/1/2024	Sell	1,403	$7.20	$10,101.60	63,717

Vanina de Verneuil Buying and Selling Activity at Vir Biotechnology

Vir Biotechnology Company Overview

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Today's Range

Now: $6.12

$6.01

$6.26

50 Day Range

MA: $6.90

$5.19

$9.85

2 Week Range

Now: $6.12

$4.95

$14.45

Volume

876,317 shs

Average Volume

1,340,621 shs

Market Capitalization

$844.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14